clinical trial · NCT06008197
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Colorado Prevention Center·phase3·recruiting·n = 5,200
Heart FailureAcute Heart FailureFinerenonePlacebo
brief summary
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.
started
Jan 17, 2024
primary completion
Nov 1, 2027
completion
Dec 1, 2027
last updated
May 6, 2026
detailed description
This is an international, randomized, double-blind, placebo-controlled, event-driven trial of finerenone for the treatment of hospitalized heart failure patients with mildly reduced or preserved ejection fraction.
official title
Randomized Trial to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Heart Failure Patients With Left Ventricular Ejection Fraction Greater Than or Equal to 40% Hospitalized Due to an Episode of Acute Decompensated Heart Failure (REDEFINE-HF)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol